Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,774 GBX | -0.20% | -0.03% | +22.36% |
May. 27 | US, European nations consider vaccinating workers exposed to bird flu | RE |
May. 24 | British Stocks Extend Losing Streak Amid Retail Sales Slump | MT |
Sales 2024 * | 31.63B 40.38B | Sales 2025 * | 33.58B 42.88B | Capitalization | 72.36B 92.4B |
---|---|---|---|---|---|
Net income 2024 * | 5.54B 7.08B | Net income 2025 * | 6.49B 8.29B | EV / Sales 2024 * | 2.68 x |
Net Debt 2024 * | 12.28B 15.68B | Net Debt 2025 * | 9.06B 11.57B | EV / Sales 2025 * | 2.42 x |
P/E ratio 2024 * |
12.9
x | P/E ratio 2025 * |
11.1
x | Employees | 70,212 |
Yield 2024 * |
3.44% | Yield 2025 * |
3.56% | Free-Float | 94.54% |
Latest transcript on GSK plc
1 day | -0.20% | ||
1 week | -0.03% | ||
Current month | +6.07% | ||
1 month | +7.35% | ||
3 months | +5.97% | ||
6 months | +24.74% | ||
Current year | +22.36% |
Managers | Title | Age | Since |
---|---|---|---|
Emma Walmsley
CEO | Chief Executive Officer | 55 | 10-04-30 |
Julie Brown
DFI | Director of Finance/CFO | 62 | 23-04-30 |
James Ford
CMP | Compliance Officer | - | 95-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Julie Brown
DFI | Director of Finance/CFO | 62 | 23-04-30 |
Jonathan Symonds
CHM | Chairman | 66 | 19-08-31 |
Hal Barron
BRD | Director/Board Member | 62 | 17-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.17% | 11 M€ | +0.83% | - | |
3.15% | 17 M€ | +7.56% | - | |
2.51% | 7 M€ | +9.75% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 1,774 | -0.20% | 4,163,301 |
24-05-23 | 1,778 | -0.59% | 6,820,675 |
24-05-22 | 1,789 | +1.85% | 10,458,110 |
24-05-21 | 1,756 | -1.07% | 8,286,400 |
Delayed Quote London S.E., May 24, 2024 at 11:35 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.36% | 92.24B | |
+38.51% | 727B | |
+31.74% | 599B | |
-6.23% | 354B | |
+18.78% | 328B | |
+1.35% | 277B | |
+16.00% | 243B | |
+8.44% | 205B | |
-5.97% | 203B | |
+6.19% | 164B |
- Stock Market
- Equities
- GSK Stock